Fundz Deep Dive
Everything you need to win FibroGen — in one platform.
Who to reach, what to say, and why now on FibroGen — plus every funding round, exec hire, and M&A move that follows, each with the verified contact and the outreach written for you.
Get the full Deep Dive on FibroGen — free.
One free Deep Dive, emailed to you. No spam; unsubscribe anytime.
Ready now? Choose your plan · Request a demo · Sign in
Engage writes the reply
Grounded in signals no one else has — tuned to their persona.
Signals no one else has
UCC liens, benefit plans, 13F holdings, permits, exec moves — fused.
Verified contact + click-to-call
The decision-maker’s email and mobile — dial in-browser.
FibroGen Sells FibroGen China to AstraZeneca for Approximately $160 Million
Feb 20, 2025•over 1 year ago
Contract Type
contract
San FranciscoDescription
FibroGen, Inc. announced the sale of its China subsidiary to AstraZeneca for approximately $160 million. The sale is aimed at strengthening the company's financial position, extending the cash runway, and allowing the progression of the clinical development program for FG-3246 and FG-3180.
Agreement Insights
Based on industry dataContract momentum indicator
Companies with recent agreements are 2.3x more likely to make additional purchases within 6 months